---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-22-000016"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2022-06-17T23:59:59+00:00"
generated_at: "2026-06-25T00:50:33.205467+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience amends arrangement agreement with Emerald Health Therapeutics, appoints new board and changes auditor

## Summary
- Filed amendment to Arrangement Agreement with Emerald Health Therapeutics waiving closing conditions and revising post-closing board.
- Dismissed Mayer Hoffman and engaged Friedman LLP as independent auditor for fiscal year 2022.
- Post-closing board includes Punit Dhillon, Bobby Rai, Praveen Tyle, Margaret Dalesandro, Keith Ward; management unchanged.
- Amendment removes requirement for waiver of change of control payments from Emerald Health Biotechnology Espana S.L.

## SEC filing metadata
- accession: 0001516551-22-000016
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2022-06-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 4.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655122000016/0001516551-22-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655122000016/skye-20220614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-22-000016
- JSON: https://secwatch.observer/filing/0001516551-22-000016.json
- Plain text: https://secwatch.observer/filing/0001516551-22-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.